SMO and meningioma: Although our growing knowledge of the genetic landscape of meningiomas has so far not translated into effective novel therapeutic approaches, the identification of novel targets and the stratification of patients based on the genetic markup of their tumors will ultimately help improve patient outcomes, and several new clinical trials (such as FAK (Focal adhesion kinase) inhibitors for SMO- or NF2-mutant meningiomas) are currently underway.